NASDAQ:NURO - Neurometrix Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.07 +0.01 (+0.94 %) (As of 03/26/2019 04:00 PM ET)Previous Close$1.06Today's Range$1.03 - $1.0952-Week Range$0.60 - $1.89Volume62,608 shsAverage Volume98,920 shsMarket Capitalization$8.43 millionP/E Ratio15.29Dividend YieldN/ABeta0.64 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts. Receive NURO News and Ratings via Email Sign-up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NURO Previous Symbol CUSIPN/A CIK1289850 Webwww.neurometrix.com Phone781-890-9989Debt Debt-to-Equity RatioN/A Current Ratio1.94 Quick Ratio1.46Price-To-Earnings Trailing P/E Ratio15.29 Forward P/E Ratio-2.61 P/E GrowthN/A Sales & Book Value Annual Sales$16.09 million Price / Sales0.52 Cash Flow$0.0240 per share Price / Cash Flow44.66 Book Value$0.79 per share Price / Book1.35Profitability EPS (Most Recent Fiscal Year)N/A Net Income$20,000.00 Net Margins0.14% Return on Equity0.31% Return on Assets0.19%Miscellaneous Employees42 Outstanding Shares7,880,000Market Cap$8.43 million Next Earnings Date4/19/2019 (Estimated) OptionableNot Optionable Neurometrix (NASDAQ:NURO) Frequently Asked Questions What is Neurometrix's stock symbol? Neurometrix trades on the NASDAQ under the ticker symbol "NURO." When did Neurometrix's stock split? How did Neurometrix's stock split work? Neurometrix shares reverse split on the morning of Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split. How were Neurometrix's earnings last quarter? Neurometrix Inc (NASDAQ:NURO) issued its earnings results on Thursday, January, 24th. The medical device company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.06. The medical device company earned $3.73 million during the quarter, compared to the consensus estimate of $5.18 million. Neurometrix had a net margin of 0.14% and a return on equity of 0.31%. View Neurometrix's Earnings History. When is Neurometrix's next earnings date? Neurometrix is scheduled to release their next quarterly earnings announcement on Friday, April 19th 2019. View Earnings Estimates for Neurometrix. What is the consensus analysts' recommendation for Neurometrix? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurometrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurometrix. Has Neurometrix been receiving favorable news coverage? Media headlines about NURO stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Neurometrix earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave headlines about the medical device company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future. Who are some of Neurometrix's key competitors? Some companies that are related to Neurometrix include Valeritas (VLRX), Nephros (NEPH), Hancock Jaffe Laboratories (HJLI), SANUWAVE Health (SNWV), PAVmed (PAVM), Restoration Robotics (HAIR), Lianluo Smart (LLIT), Interpace Diagnostics Group (IDXG), DarioHealth (DRIO), Atossa Genetics (ATOS), Dynatronics (DYNT), Invivo Therapeutics (NVIV), Biostage (BSTG), Alliqua Biomedical (ALQA) and Presbia (LENS). What other stocks do shareholders of Neurometrix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurometrix investors own include Merit Medical Systems (MMSI), SLS International (SLS), Citigroup (C), TrovaGene (TROV), xG Technology (XGTI), OraSure Technologies (OSUR), Rewalk Robotics (RWLK), salesforce.com (CRM), Advanced Micro Devices (AMD) and InspireMD (NSPR). Who are Neurometrix's key executives? Neurometrix's management team includes the folowing people: Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 54)Mr. Thomas T. Higgins, Sr. VP, CFO & Treasurer (Age 67)Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 58)Mr. Richard J. Thomas, PresMr. Michael J. MacDonald, Sr. VP & GM of Diagnostics How do I buy shares of Neurometrix? Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neurometrix's stock price today? One share of NURO stock can currently be purchased for approximately $1.07. How big of a company is Neurometrix? Neurometrix has a market capitalization of $8.43 million and generates $16.09 million in revenue each year. Neurometrix employs 42 workers across the globe. What is Neurometrix's official website? The official website for Neurometrix is http://www.neurometrix.com. How can I contact Neurometrix? Neurometrix's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected] MarketBeat Community Rating for Neurometrix (NASDAQ NURO)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 201 (Vote Outperform)Underperform Votes: 145 (Vote Underperform)Total Votes: 346MarketBeat's community ratings are surveys of what our community members think about Neurometrix and other stocks. Vote "Outperform" if you believe NURO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NURO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: What does the Producer Price Index (PPI) tell investors?